Mibefradil

Drug Profile

Mibefradil

Alternative Names: Batenac®; Befral®; Cerate®; Mibefradil dihydrochloride; Posicor®; Quota®; RO 40-5967; Taxben®

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Cavion
  • Class Antihypertensives; Benzimidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrahydronaphthalenes; Vasodilators
  • Mechanism of Action Cell division modulators; DNA repair inhibitors; T type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Ovarian cancer; Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal Angina pectoris; Hypertension
  • No development reported Glioblastoma; Glioma; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Discontinued Arrhythmias; Heart failure

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioblastoma(Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ovarian-cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top